EUVIMEDEUVIMED entdecken
Open Access

Formation of tertiary lymphoid structures drives Parkin antitumor immunity

Michela Perego iD, Andrew V Kossenkov iD, Jagadish C Ghosh iD, Chiara Camisaschi iD, Nicholas J Tursi iD, David B Weiner iD, Dario C Altieri iD

Science Advances · 07.08.2026 · 12 (32)

DOI: 10.1126/sciadv.aef3194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 07.08.2026. Verfasst von Michela Perego und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genome Regulation and Cell Signaling Program, The Wistar Institute, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Tertiary Lymphoid Structures, Prostatic Neoplasms. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondria activate immunity, but the role in cancer is unknown. Here, we report that transgenic expression of Parkin, a regulator of mitochondrial fitness, induces inflammation and interferon (IFN) gene signatures, suppresses prostate cancer formation and generates CD8 + and CD20 + intraprostatic immune aggregates. These had hallmarks of mature tertiary lymphoid structures (TLS), expressing markers of B cell maturation (CXCL13, CCL21), germinal center formation (BCL6, GL7), mature dendritic cells (MHC-II/CD208) and high endothelial venules (LYVE-1). Parkin TLS showed high Ig gene expression, recruitment of CXCR5 + follicular T helper cells and expansion of CD69 + /KLRG1 + effector T cells. Conditioned medium from Parkin-positive cells expanded memory B and plasma cells, increased IgG1 production, and sustained B and T cell migration. Finally, conditional expression of Parkin induced TLS formation, upregulated Ig chains and inhibited prostate cancer growth, in vivo, whereas Parkin reconstitution in IFNAR1, CD8 or CD20 knockout mice had no effect. Therefore, mitochondrial immunity orchestrates antitumor responses, and TLS formation contributes to tumor suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesTertiary Lymphoid StructuresProstatic NeoplasmsAnimalsMaleMiceMitochondriaHumansB-Lymphocytes

Substanzen

parkin proteinUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Genome Regulation and Cell Signaling Program, The Wistar Institute, Philadelphia, PA 19104.
  • Bioinformatics Shared Resource, The Wistar Institute, Philadelphia, PA 19104.
  • Flow Cytometry Core, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Vaccine and Immunotherapy Center, The Wistar institute, Philadelphia, PA 19104.

ORCID-Profile: Michela Perego, Andrew V Kossenkov, Jagadish C Ghosh, Chiara Camisaschi, Nicholas J Tursi, David B Weiner, Dario C Altieri

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Perego, M., Kossenkov, A. V., Ghosh, J. C., Camisaschi, C., Tursi, N. J., Weiner, D. B., & Altieri, D. C. (2026). Formation of tertiary lymphoid structures drives Parkin antitumor immunity. Science Advances, 12(32). https://doi.org/10.1126/sciadv.aef3194

Vancouver

Perego M, Kossenkov AV, Ghosh JC, Camisaschi C, Tursi NJ, Weiner DB, et al. Formation of tertiary lymphoid structures drives Parkin antitumor immunity. Science Advances. 2026;12(32). doi:10.1126/sciadv.aef3194

BibTeX
@article{Perego2026,
  author = {Perego, Michela and Kossenkov, Andrew V and Ghosh, Jagadish C and Camisaschi, Chiara and Tursi, Nicholas J and Weiner, David B and Altieri, Dario C},
  title = {Formation of tertiary lymphoid structures drives Parkin antitumor immunity},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {32},
  doi = {10.1126/sciadv.aef3194}
}
Kostenlos starten →